| Inclusion Criteria: | 1) Age > 18 years old. This study was written for an adult population (the incidence of this disease in the pediatric population is rare.
2) Recurrent EOC or PPC with histologic confirmation of the original tumor. Recurrent disease may be manifested as an elevated CA-125 using the following criteria (Vergote et al., 2000): (A) Increase in CA-125 to at least 2x the ULN (assayed on 2 occasions at least 7 days apart) for subjects with a history of normal pre-treatment values or values that normalized with most recent treatment. -OR- (B) Increase in CA-125 to 2x the lowest observed value on most recent treatment (assayed on two occasions at least 7 days apart) for subjects whose CA-125 did not normalize with most recent treatment.
3) Platinum-resistant disease, defined as recurrence less than six months after discontinuation of treatment with platinum therapy or platinum-refractory disease, defined as progression on a platinum-containing regimen.
4) A treatment-free interval of at least three weeks for cytotoxic therapies, radiation therapy, or other experimental drugs prior to first treatment on this protocol.
5) A Zubrod performance status of two or less.
6) Patients with known hypersensitivity to platinum compounds, who have failed a desensitization regimen, or in the opinion of the investigator, are not good candidates for desensitization, are eligible. |